Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Risk-Benefit Guidance Aims To Improve Pre-Market Review Predictability

This article was originally published in The Gray Sheet

Executive Summary

It takes more than safety and effectiveness data alone for FDA device reviewers to determine how benefits stack up against risks in a pre-market submission, the agency accentuates in new draft guidance.

You may also be interested in...

FDA’s Final Risk-Benefit Guidance Excludes 510(k)s, Adds De Novo Petitions

Device center reviewers will begin applying the guidance to incoming PMA and de novo submissions and to submissions already under review with decisions beginning on May 1.

Obesity Devices: Planned Risk-Tolerance Survey Could Impact CDRH Decision-Making

A planned survey evaluating obese patients’ tolerance for risk fits into a broader initiative by CDRH to reassess, and in some cases rebalance, how it weighs risks and benefits when making regulatory decisions.

Risk And Benefit, Quantified: CDRH Expands Use Of New Statistical Framework

Decision analysis tools will be put into practice as part of the device center’s priority “innovation pathway” for breakthrough devices and in a pilot program focused on obesity devices. The techniques may allow for shorter development and review cycles, among other benefits, CDRH says.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts